PL3082858T3 - Środek wiążący adrenomedulinę do zastosowania w terapii nowotworu - Google Patents

Środek wiążący adrenomedulinę do zastosowania w terapii nowotworu

Info

Publication number
PL3082858T3
PL3082858T3 PL14830958T PL14830958T PL3082858T3 PL 3082858 T3 PL3082858 T3 PL 3082858T3 PL 14830958 T PL14830958 T PL 14830958T PL 14830958 T PL14830958 T PL 14830958T PL 3082858 T3 PL3082858 T3 PL 3082858T3
Authority
PL
Poland
Prior art keywords
adrenomedullin
cancer
therapy
binder
adrenomedullin binder
Prior art date
Application number
PL14830958T
Other languages
English (en)
Inventor
Andreas Bergmann
Original Assignee
Angiobiomed Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49876456&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3082858(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Angiobiomed Gmbh filed Critical Angiobiomed Gmbh
Publication of PL3082858T3 publication Critical patent/PL3082858T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL14830958T 2013-12-20 2014-12-19 Środek wiążący adrenomedulinę do zastosowania w terapii nowotworu PL3082858T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13199000 2013-12-20
EP14830958.6A EP3082858B1 (en) 2013-12-20 2014-12-19 Adrenomedullin binder for use in therapy of cancer
PCT/EP2014/078870 WO2015092021A1 (en) 2013-12-20 2014-12-19 Adrenomedullin binder for use in therapy of cancer

Publications (1)

Publication Number Publication Date
PL3082858T3 true PL3082858T3 (pl) 2021-09-27

Family

ID=49876456

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14830958T PL3082858T3 (pl) 2013-12-20 2014-12-19 Środek wiążący adrenomedulinę do zastosowania w terapii nowotworu

Country Status (6)

Country Link
US (1) US10793626B2 (pl)
EP (1) EP3082858B1 (pl)
JP (1) JP6673847B2 (pl)
ES (1) ES2865303T3 (pl)
PL (1) PL3082858T3 (pl)
WO (1) WO2015092021A1 (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4061944A1 (en) * 2019-11-22 2022-09-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Inhibitors of adrenomedullin for the treatment of acute myeloid leukemia by eradicating leukemic stem cells
US20210285949A1 (en) * 2020-03-16 2021-09-16 Sphingotec Gmbh Pro-adrenomedullin or fragment thereof in patients infected with corona virus and treatments with binder against adrenomedullin

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0845036B1 (en) * 1995-08-18 1999-06-02 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Functional role of adrenomedullin (am) and the gene-related product (pamp) in human pathology and physiology
US20050175619A1 (en) * 2004-02-05 2005-08-11 Robert Duffy Methods of producing antibody conjugates
TWI388568B (zh) * 2006-02-10 2013-03-11 Genentech Inc 抗ｆｇｆ１９抗體及其使用方法
RS64060B1 (sr) * 2011-11-16 2023-04-28 Adrenomed Ag Antitelo na anti-adrenomedulin (adm) ili fragment antitela na adm ili struktura antitela na adm bez ig za sprečavanje ili smanjenje disfunkcije organa ili insuficijencije organa kod pacijenta koji ima hroničnu ili akutnu bolest ili akutno stanje
US9402900B2 (en) * 2011-11-16 2016-08-02 Adrenomed Ag Methods of modulating adrenomedullin by administering an anti-adrenomedullin (ADM) antibody

Also Published As

Publication number Publication date
WO2015092021A1 (en) 2015-06-25
ES2865303T3 (es) 2021-10-15
EP3082858A1 (en) 2016-10-26
US20160319007A1 (en) 2016-11-03
EP3082858B1 (en) 2021-01-27
JP6673847B2 (ja) 2020-03-25
JP2017508781A (ja) 2017-03-30
US10793626B2 (en) 2020-10-06

Similar Documents

Publication Publication Date Title
IL274318A (en) Cancer treatment with rapamycin target site kinase inhibitors
IL245731A0 (en) Combined treatment for cancer
GB2516814B (en) Use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer
GB201322725D0 (en) Cancer therapy
SG10201801433XA (en) Composition and vaccine for treating prostate cancer
DK3010519T3 (en) Oncolytic adenovirus for use in a treatment of brain cancer
IL245281A0 (en) Methods and preparations for the treatment of cancer
ZA201406708B (en) Treatment of cancer with tor kinase inhibitors
ZA201406706B (en) Treatment of cancer with tor kinase inhibitors
IL234641A0 (en) Cancer treatment with rapamycin target site kinase inhibitors
SG11201509707QA (en) Cancer therapy
IL244353A0 (en) Compounds and use for cancer treatment
SG11201507847UA (en) Cancer therapy
SG11201508878WA (en) Methods of treating cancer
ZA201507755B (en) Tumor-selective combination therapy
IL238453A0 (en) Trans-clomiphene for use in cancer treatment
PL3071192T3 (pl) Związek kurkufenol do zastosowania w leczeniu nowotworu
EP2961412A4 (en) CANCER THERAPY
SG10201703977UA (en) Methods of treating cancer
SI2872176T1 (sl) Karboranilporfirin za uporabo pri zdravljenju raka
PL3082858T3 (pl) Środek wiążący adrenomedulinę do zastosowania w terapii nowotworu
GB201518731D0 (en) Tumour Therapy
GB201317213D0 (en) Cancer Therapy
GB201322958D0 (en) Uses of oligouronates in cancer treatment
PL3010513T3 (pl) Skojarzenie RO5503781 i kapecytabiny do leczenia raka